These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3136608)

  • 21. Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
    Cryz SJ; Sadoff JC; Ohman D; Fürer E
    J Lab Clin Med; 1988 Jun; 111(6):701-7. PubMed ID: 3131471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule.
    Göcke K; Baumann U; Hagemann H; Gabelsberger J; Hahn H; Freihorst J; von Specht BU
    FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):167-71. PubMed ID: 12832121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy.
    Lee NG; Jung SB; Ahn BY; Kim YH; Kim JJ; Kim DK; Kim IS; Yoon SM; Nam SW; Kim HS; Park WJ
    Vaccine; 2000 Mar; 18(18):1952-61. PubMed ID: 10699346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
    von Specht B; Knapp B; Hungerer K; Lücking C; Schmitt A; Domdey H
    J Biotechnol; 1996 Jan; 44(1-3):145-53. PubMed ID: 8717398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine.
    Jang IJ; Kim IS; Park WJ; Yoo KS; Yim DS; Kim HK; Shin SG; Chang WH; Lee NG; Jung SB; Ahn DH; Cho YJ; Ahn BY; Lee Y; Kim YG; Nam SW; Kim HS
    Vaccine; 1999 Jan; 17(2):158-68. PubMed ID: 9987150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously.
    Edelman R; Taylor DN; Wasserman SS; McClain JB; Cross AS; Sadoff JC; Que JU; Cryz SJ
    Vaccine; 1994 Nov; 12(14):1288-94. PubMed ID: 7856293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enzyme-linked immunosorbent assay antibody responses to a temperature-sensitive mutant of Pseudomonas aeruginosa.
    Sordelli DO; Rojas RA; Cerquetti MC; Hooke AM; Degnan PJ; Bellanti JA
    Infect Immun; 1985 Oct; 50(1):324-7. PubMed ID: 3930404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of a Pseudomonas aeruginosa outer membrane protein I vaccine in human volunteers.
    von Specht BU; Lücking HC; Blum B; Schmitt A; Hungerer KD; Domdey H
    Vaccine; 1996 Aug; 14(12):1111-7. PubMed ID: 8911006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of a fusion protein containing PilQ and disulphide turn region of PilA from Pseudomonas aeruginosa in mice.
    Gholami M; Chirani AS; Razavi S; Falak R; Irajian G
    Lett Appl Microbiol; 2017 Nov; 65(5):439-445. PubMed ID: 28857243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.
    Larbig M; Mansouri E; Freihorst J; Tümmler B; Köhler G; Domdey H; Knapp B; Hungerer KD; Hundt E; Gabelsberger J; von Specht BU
    Vaccine; 2001 Mar; 19(17-19):2291-7. PubMed ID: 11257350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Production and study of the properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine. IV. The effect of immunization with Pseudomonas aeruginosa vaccine on the immune status of volunteer donors].
    Titova TI; Sidorova TN; Radkevich SA; Antsiferova NG; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Aug; (8):80-4. PubMed ID: 3933225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine.
    Zuercher AW; Imboden MA; Jampen S; Bosse D; Ulrich M; Chtioui H; Lauterburg BH; Lang AB
    Clin Exp Immunol; 2005 Nov; 142(2):381-7. PubMed ID: 16232228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients.
    Mansouri E; Blome-Eberwein S; Gabelsberger J; Germann G; von Specht BU
    FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):161-6. PubMed ID: 12832120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Local IgA and IgG response to intratracheal immunization with Pseudomonas aeruginosa antigens.
    Johansen HK; Høiby N
    APMIS; 1992 Jan; 100(1):87-90. PubMed ID: 1536724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study.
    Baumann U; Göcke K; Gewecke B; Freihorst J; von Specht BU
    Respir Res; 2007 Aug; 8(1):57. PubMed ID: 17683588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study of the immunogenicity of the Pseudomonas aeruginosa polyvalent corpuscular vaccine in human volunteers.
    Meitert E; Meitert T; Petrovici M; Sima F; Savulian C; Mitrică N; Georgescu C; Costache G
    Arch Roum Pathol Exp Microbiol; 1979; 38(3-4):309-16. PubMed ID: 122593
    [No Abstract]   [Full Text] [Related]  

  • 37. [Results of using polyvalent Pseudomonas aeruginosa vaccine in children with burns by various medical centers].
    Bbukowska D; Serafińska D; Rudowski W; Hoffman S; Olański W; Gardzińska E; Popiel D; Jedrzejczak G; Czarnecka I
    Pol Tyg Lek; 1989 Oct 23-Nov 6; 44(43-45):924-7. PubMed ID: 2518666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody response of fibrocystic patients to homologous 0-typable and 0-defective isolates of Pseudomonas aeruginosa.
    MacDougall J; Hodson ME; Pitt TL
    J Clin Pathol; 1990 Jul; 43(7):567-71. PubMed ID: 1696291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of Klebsiella pneumoniae K1 capsular polysaccharide vaccine in humans.
    Cryz SJ; Fürer E; Germanier R
    J Infect Dis; 1985 Apr; 151(4):665-71. PubMed ID: 3882856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Local Immune response in rabbits following enteral immunization with live attenuated bacterial Enterobacteriaceae vaccines].
    Dentschev W; Marinova S; Sumerska T; Nenkov P; Koitschev T; Trifonowa A
    Arch Exp Veterinarmed; 1980; 34(1):9-13. PubMed ID: 6998404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.